Ordering Buffered 3% Hypertonic Saline for Neuro Patients
The described protocol for ordering buffered 3% hypertonic saline (250 mL bolus) is appropriate for neuro patients with elevated intracranial pressure, as hypertonic saline is effective at reducing ICP and should be used instead of mannitol for this indication. 1
Clinical Rationale for Buffered Hypertonic Saline
The buffering of hypertonic saline with sodium acetate reduces chloride exposure while maintaining equivalent hyperosmolar effects. Buffered hypertonic saline with sodium acetate maintains similar hyperosmolarity to standard 3% hypertonic saline (average osmolality increase of 20.3 mOsm/kg vs 21.1 mOsm/kg after 72 hours) while significantly reducing hyperchloremia. 2 This is clinically important because hyperchloremia is associated with decreased renal perfusion and increased risk of acute kidney injury. 2
Ordering Protocol Validation
The step-by-step protocol described is clinically sound:
Starting with 0.9% NaCl 250 mL bag as the base fluid is appropriate, as isotonic crystalloids are recommended as first-line fluid therapy in acute brain injury patients. 3
The addition of 32 mEq sodium acetate (32 mL of 2 mEq/mL) and 32 mEq NaCl from 23.4% solution (8 mL of 4 mEq/mL) to 210 mL of 0.9% NaCl creates the appropriate buffered 3% hypertonic solution. 4
The final volume of 250 mL is consistent with the most commonly studied bolus dose in clinical trials for ICP reduction. 1
Administration Considerations
Hypertonic saline boluses are effective at reducing raised intracranial pressure (Grade A evidence), though they do not improve neurological outcomes or survival. 1 The median ICP reduction is approximately 6 mm Hg after 3% hypertonic saline bolus administration. 5
Route of Administration
Rapid bolus administration of 3% hypertonic saline via peripheral IV at rates up to 999 mL/hour is safe, with minimal complications (3.7% incidence, primarily injection site pain at 1.9%). 5, 6 This allows for more rapid treatment initiation compared to waiting for central venous access. 5
For 23.4% hypertonic saline specifically, administration over 2-5 minutes via central or peripheral line is well tolerated with rare incidence of hypotension (16%), bradycardia (3%), or infusion site reactions. 7
Safety Monitoring
Serum sodium levels should be measured within 6 hours of bolus administration, and re-administration should not occur until serum sodium is <155 mmol/L. 1 The majority of patients have peak sodium levels <155 mmol/L, with levels typically returning to normal by 24 hours. 1
When switching from standard 3% hypertonic saline to buffered formulation, serum chloride levels decrease by an average of 2.5 mEq/L after 24 hours and remain below baseline, whereas standard 3% hypertonic saline causes chloride levels to increase by 4.3 mEq/L and continue rising. 2
Dosing Efficacy
The mean dose of 3% hypertonic saline required to reduce ICP below 15 mm Hg is 1.4 mL/kg, with a mean time to effect of 16 minutes. 8 This makes it more effective than 20% mannitol (2.0 mL/kg over 23 minutes) for the same indication. 8
Critical Pitfalls to Avoid
Never use hypotonic solutions (<280 mOsm/L) such as Ringer's Lactate in acute brain injury patients due to risk of cerebral edema. 3
Do not administer hypertonic saline if serum sodium is already ≥155 mmol/L without reassessing the clinical situation. 1
Ensure proper dilution calculations are verified by pharmacy before administration—the 23.4% NaCl concentration is 4 mEq/mL, requiring careful calculation. 4
Monitor for overcorrection, though osmotic demyelination syndrome has not been documented even with sodium levels up to 170.7 mmol/L in studies. 1